Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Implantable pump could ease diabetes management for 40 patients

NCT ID NCT06739811

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study is testing a new implantable insulin pump (MIIPS 2020) in 40 adults with type 1 diabetes whose blood sugar is hard to control with standard insulin shots or external pumps. The pump is placed inside the body and delivers insulin directly, aiming to reduce dangerous high and low blood sugar episodes. The main goal is to see how accurately the pump delivers insulin over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is aged ≥ 18 years old. 2. Subject has a clinical diagnosis of type 1 diabetes for ≥ 6 months prior to screening as determined via medical record or source documentation by an individual qualified to make a medical diagnosis. 3. Subject with type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), presenting with frequent, otherwise unexplained severe hyper-and/or hypoglycaemia. 4. Subject has access to a reliable support person, defined as an individual who has daily contact with the subject and knows who to contact in the event of an emergency (i.e., caregiver). 5. Subject has the physical and intellectual ability (in the opinion of the study investigator) to operate the MIIP system and to comply with the data reporting requirements of the study. 6. Subject is willing and able to sign and date informed consent, comply with all study procedures as required during the study. Exclusion Criteria: 1. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device before enrollment into this study, that could impact the outcomes of this study; as per investigator and sponsor judgment. 2. Subject has any other disease or condition that may increase risks during the implant procedure or may preclude the subject from participating in the study, as determined by a physician who is not the principal investigator. 3. Subject has any known or suspected allergy to insulin or implantable materials of the MIIPS (pump and catheter) as determined by a physician. 4. Subject is a woman who is pregnant, or of childbearing potential, or lactating, and who is neither surgically sterile, nor using contraceptives (devices, oral, implanted or other physician-approved contraceptive), or willing to use them, at the time of enrollment. 5. Subject is vulnerable, legally incompetent or illiterate. 6. Residence or planned non-pressurized travel at elevations above 10000 feet/3048 meters (commercial airline travel is acceptable). 7. Planning to engage in activities requiring a descent greater than or equal to 10 feet/3 meters below sea level. 8. Subject has an active infection requiring antibiotic treatment. 9. Subject is a person whose body size is not sufficient to accept implantable pump bulk and weight. 10. Subject has a life expectancy of less than 9 months. 11. Subject has diagnosis of illicit drugs abuse disorder. 12. Subject has diagnosis of marijuana abuse disorder. 13. Subject has diagnosis of prescription drugs abuse disorder. 14. Subject has diagnosis of alcohol abuse disorder. 15. Subject who is unwilling or unable to monitor their glucose level or wear a personal continuous glucose monitor. 16. Subject who is unwilling or unable to make programming modifications to the pump based on glucose level readings.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type I diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Dijon Bourgogne

    RECRUITING

    Dijon, 21100, France

  • CHU Lille - Hôpital Huriez

    NOT_YET_RECRUITING

    Lille, France, 59037, France

  • CHU de Nancy - Hôpital d'Adultes de Brabois

    NOT_YET_RECRUITING

    Nancy, France, 54511, France

  • CHU de Toulouse - Hôpital Rangueil

    RECRUITING

    Toulouse, France, 31059, France

  • Centre Hospitalier Sud Francilien

    NOT_YET_RECRUITING

    Corbeil-Essonnes, France, 91100, France

  • Centre Hospitalier Universitaire De Montpellier

    RECRUITING

    Montpellier, France, 34295, France

  • Hôpital Européen Marseille

    RECRUITING

    Marseille, 13003, France

  • Hôpital Lariboisière & Fernand-Widal

    RECRUITING

    Paris, France

  • Hôpital Saint André -Centre Hospitalier Universitaire de Bordeaux

    NOT_YET_RECRUITING

    Bordeaux, France, 33000, France

  • Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil

    RECRUITING

    Strasbourg, France

  • Isala Zwolle

    RECRUITING

    Zwolle, Netherlands, 8025 AB, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.